Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fostemsavir Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

NCT02674581
View directory record Official record
Conditions
HIV Infections
Interventions
Oral BMS-663068 (pro-drug)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

NCT02859259
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

NCT02164045
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 6, 2026, 12:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

NCT02362503
View directory record Official record
Conditions
HIV Infections
Interventions
BMS-663068, Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
39
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

NCT02480881
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Oral Contraceptive, Loestrin 1.5/30
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 6, 2026, 12:24 PM EDT
Active, not recruiting Phase 4 Interventional

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

NCT05220358
View directory record Official record
Conditions
HIV-1-infection
Interventions
Fostemsavir 600 MG [Rukobia]
Drug
Lead sponsor
Orlando Immunology Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 6, 2026, 12:24 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 6, 2026, 12:24 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Fostemsavir (FTR), SOC INSTI-based ART
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Bakersfield, California • San Diego, California • Ft. Pierce, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

NCT02277600
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Darunavir, Cobicistat
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

NCT04757974
View directory record Official record
Conditions
HIV Infections
Interventions
Fostemsavir 600 mg, Fostemsavir 200 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

NCT02666001
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Methadone, Buprenorphine and Norbuprenorphine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

NCT02666053
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction (DDI) Rifabutin

NCT02138084
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Rifabutin, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 6, 2026, 12:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

NCT04648280
View directory record Official record
Conditions
HIV Infections With Multi Drug Resistant Virus
Interventions
Fostemsavir
Drug
Lead sponsor
PENTA Foundation
Network
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

NCT02480894
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 6, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT02467335
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 6, 2026, 12:24 PM EDT